Endocrine Abstracts

Understanding the mechanisms that underly prostate cancer initiation and progression requires a comprehensive annotation of the cancer genome. While most research has focused on protein coding genes, there is increasing basic and clinical evidence that the much larger non-coding genome plays a critical role in prostate cancer tumourigenesis. The non-coding genome harbours numerous functional elements that regulate the expression of all protein-coding genes, including oncogenes...

Lineage plasticity has been postulated to contribute to the failure of targeted- and immuno-therapies. In prostate cancer (PCa), the discovery that advanced metastatic castration-resistant PCa (CRPC) classified as adenocarcinoma remains fueled by the androgen receptor (AR) has ushered the development of potent AR pathway inhibitors (ARPIs), notably abiraterone and enzalutamide undoubtedly benefiting the survival of patients with advanced disease. However, a subset of patients ...

Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and a leading cause of male mortality. The androgen receptor (AR) remains the major therapeutic target with therapies that inhibit the AR signaling axis improving the outcome for patients with advanced castration-sensitive and castration-resistance prostate cancer. Despite these advances, primary and secondary resistance to AR targeting therapies is common, with evidence of ongoing AR signaling in t...